OnCo
key papersKey paper

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

The UK trial that showed a second chemotherapy, FOLFOX, helps people with advanced bile duct or gallbladder cancer live about a month longer on average once gemcitabine and cisplatin stop working, with one in four alive at a year instead of one in nine.